TransMedics Group (NASDAQ:TMDX) Research Coverage Started at Barclays

by · The Markets Daily

Barclays started coverage on shares of TransMedics Group (NASDAQ:TMDX – Free Report) in a research report sent to investors on Wednesday morning, MarketBeat.com reports. The firm issued an overweight rating and a $120.00 target price on the stock.

Several other equities analysts also recently commented on TMDX. Needham & Company LLC reiterated a “buy” rating on shares of TransMedics Group in a research report on Friday, September 11th. Piper Sandler reissued an “overweight” rating and set a $100.00 price target (down from $120.00) on shares of TransMedics Group in a research note on Wednesday, August 5th. Stifel Nicolaus boosted their price target on TransMedics Group from $75.00 to $80.00 and gave the stock a “hold” rating in a report on Thursday, June 18th. Zacks Research downgraded TransMedics Group from a “hold” rating to a “strong sell” rating in a research note on Monday, July 6th. Finally, UBS Group dropped their price objective on shares of TransMedics Group from $80.00 to $77.00 and set a “neutral” rating for the company in a report on Wednesday, August 5th. Six equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $121.00.

Read Our Latest Stock Report on TMDX

TransMedics Group Stock Performance

NASDAQ TMDX opened at $77.87 on Wednesday. The firm’s fifty day moving average price is $86.01 and its two-hundred day moving average price is $83.93. The stock has a market cap of $2.69 billion, a PE ratio of 20.02, a PEG ratio of 1.09 and a beta of 1.94. The company has a debt-to-equity ratio of 1.62, a quick ratio of 6.07 and a current ratio of 6.62. TransMedics Group has a fifty-two week low of $60.10 and a fifty-two week high of $156.00.

TransMedics Group (NASDAQ:TMDX – Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $0.44 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06). TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The firm had revenue of $189.95 million during the quarter, compared to the consensus estimate of $184.00 million. During the same quarter in the previous year, the company posted $0.92 earnings per share. The firm’s revenue was up 20.7% on a year-over-year basis. On average, equities analysts expect that TransMedics Group will post 1.46 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director David Weill bought 1,336 shares of the stock in a transaction that occurred on Friday, September 11th. The stock was acquired at an average cost of $81.63 per share, with a total value of $109,057.68. Following the transaction, the director directly owned 16,392 shares in the company, valued at approximately $1,338,078.96. This trade represents a 8.87% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 6.90% of the stock is owned by insiders.

Institutional Investors Weigh In On TransMedics Group

A number of institutional investors have recently made changes to their positions in TMDX. Dimensional Fund Advisors LP raised its position in shares of TransMedics Group by 5.5% during the first quarter. Dimensional Fund Advisors LP now owns 516,679 shares of the company’s stock worth $51,355,000 after acquiring an additional 26,969 shares during the last quarter. Braidwell LP boosted its holdings in TransMedics Group by 85.1% in the second quarter. Braidwell LP now owns 609,715 shares of the company’s stock valued at $40,497,000 after acquiring an additional 280,324 shares during the last quarter. Wasatch Advisors LP boosted its holdings in TransMedics Group by 4.3% in the first quarter. Wasatch Advisors LP now owns 346,144 shares of the company’s stock valued at $34,410,000 after acquiring an additional 14,296 shares during the last quarter. Wellington Management Group LLP increased its position in TransMedics Group by 6.1% during the 2nd quarter. Wellington Management Group LLP now owns 515,973 shares of the company’s stock valued at $34,271,000 after purchasing an additional 29,500 shares during the period. Finally, Principal Financial Group Inc. increased its position in TransMedics Group by 19.4% during the 1st quarter. Principal Financial Group Inc. now owns 231,433 shares of the company’s stock valued at $23,007,000 after purchasing an additional 37,656 shares during the period. Institutional investors own 99.67% of the company’s stock.

About TransMedics Group

(Get Free Report)

TransMedics Group, Inc is a medical technology company that develops organ transplant systems designed to preserve and assess donated organs outside the body before transplantation. Its primary platform, the Organ Care System (OCS), uses warm perfusion technology to circulate oxygenated blood and nutrients through organs, helping maintain organ function during transport and potentially expanding the pool of organs available for transplant.

The company offers OCS solutions for heart, lung and liver transplantation.

Further Reading